Patents Assigned to AstraZeneca AB
  • Physical form of a SGR modulator
    Patent number: 10407404
    Abstract: A crystalline form of 2,2-difluoro-N-[(1R,2S)-3-methyl-1-{[1-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1H-indazol-5-yl]oxy}-1-phenylbutan-2-yl]propanamide (form C), pharmaceutical compositions containing it and its use in therapy.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: September 10, 2019
    Assignee: ASTRAZENECA AB
    Inventor: Chaoyi Deng
  • [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases
    Patent number: 10407432
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 10, 2019
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors
    Patent number: 10398754
    Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: September 3, 2019
    Assignees: Pieris Pharmaceuticals GmbH, Astrazeneca AB
    Inventors: Andreas Hohlbaum, Laurent Audoly, Beverly Koller
  • Composition for Inhalation
    Publication number: 20190216828
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Application
    Filed: August 22, 2018
    Publication date: July 18, 2019
    Applicant: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • Chemical compounds
    Patent number: 10336725
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: July 2, 2019
    Assignee: AstraZeneca AB
    Inventors: Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
  • 1,3,4-thiadiazole compounds and their use in treating cancer
    Patent number: 10323028
    Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, where: Q can be 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl; R1 can be hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluoroazetidin-1-yl, 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl; R2 can be hydrogen or fluoro; R3 can be hydrogen or methoxy; and R4 can be methoxy, ethoxy, or methoxymethyl; provided that when R1 is hydrogen, methoxy or trifluoromethoxy, then R3 is not hydrogen, and/or R4 is methoxymethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: June 18, 2019
    Assignees: AstraZeneca AB, Cancer Research Technology Limited
    Inventors: Johannes Wilhelmus Maria Nissink, Maurice Raymond Verschoyle Finlay, Mark David Charles
  • Therapeutic dendrimers
    Patent number: 10314920
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: June 11, 2019
    Assignee: AstraZeneca AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William McCoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist
  • bis-Pyridazine Compounds and Their Use in Treating Cancer
    Publication number: 20190169172
    Abstract: A compound of Formula (I): or a pharmaceutically where R1 can be hydro, methoxy, difluoromethoxy or trifluoromethoxy; R2 can be hydro, methoxy, trifluoromethoxy or trifluoromethyl; and R3 can be hydro or methoxy. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
    Type: Application
    Filed: February 4, 2019
    Publication date: June 6, 2019
    Applicants: AstraZeneca AB, Cancer Research Technology Limited
    Inventor: Maurice Raymond Verschoyle Finlay
  • Compounds
    Patent number: 10301267
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: May 28, 2019
    Assignee: AstraZeneca AB
    Inventors: David Buttar, Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas
  • Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
    Patent number: 10300065
    Abstract: The present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: May 28, 2019
    Assignee: ASTRAZENECA AB
    Inventors: Lars Magnus Andersson, Tomas Lars-Gunnar Andersson, Olof Fredrik Bengtsson, Hans Peter Held, Garnet Edward Howells, Eva Christina Jensen, Robert Storey
  • Anti-IFNAR1 antibodies with reduced Fc ligand affinity
    Patent number: 10301390
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: May 28, 2019
    Assignee: AstraZeneca AB
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • 1, 3, 4-thiadiazole compounds and their use in treating cancer
    Patent number: 10294221
    Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: May 21, 2019
    Assignees: AstraZeneca AB, Cancer Research Technology Limited
    Inventors: Maurice Raymond Verschoyle Finlay, Chukuemeka Tennyson Ekwuru, Mark David Charles, Piotr Antoni Raubo, Jonathan James Gordon Winter, Johannes Wilhelmus Maria Nissink
  • Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
    Patent number: 10287258
    Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: May 14, 2019
    Assignee: ASTRAZENECA AB
    Inventors: Hans Roland Lonn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • Arginase Inhibitors and Methods of Use
    Publication number: 20190127395
    Abstract: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.
    Type: Application
    Filed: September 28, 2018
    Publication date: May 2, 2019
    Applicants: AstraZeneca AB, The Trustees of the University of Pennsylvania
    Inventors: David W. Christianson, Bruce Edward Tomczuk, Richard Scott Pottorf, Andrew Vargha Colasanti, Gary Lee Olson
  • C5-anilinoquinazoline compounds and their use in treating cancer
    Patent number: 10273227
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: April 30, 2019
    Assignee: AstraZeneca AB
    Inventors: Jason Kettle, Stuart Pearson, Martin Packer, James Smith
  • PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291
    Publication number: 20190111057
    Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically acceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
    Type: Application
    Filed: November 20, 2018
    Publication date: April 18, 2019
    Applicant: AstraZeneca AB
    Inventors: Cindy FINNIE, Steven Anthony RAW, David WILSON
  • THERAPEUTIC POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME
    Publication number: 20190092757
    Abstract: Described herein are polymeric nanoparticles that include a therapeutic agent which is 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide (also known as AZD1152 hqpa) or a pharmaceutically acceptable salt thereof, and methods of making and using such therapeutic nanoparticles.
    Type: Application
    Filed: June 27, 2018
    Publication date: March 28, 2019
    Applicant: ASTRAZENECA AB
    Inventors: Marianne Bernice ASHFORD, James Martin NOLAN, III, Eyoung SHIN, Young-Ho SONG, Greg TROIANO, Hong WANG
  • CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS
    Publication number: 20190091236
    Abstract: The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, that inhibit dipeptidyl peptidase 1 (DPP1) activity. Methods provided herein are useful for prophylaxis, increasing the lung function in a patient, and/or and/or decreasing the rate of pulmonary exacerbation in a patient. In one embodiment, the compound of Formula (I) is (2S)—N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide.
    Type: Application
    Filed: November 21, 2018
    Publication date: March 28, 2019
    Applicants: AstraZeneca AB, Insmed Incorporated
    Inventors: Hans Roland Lonn, Stephen Connolly, Steven Swallow, Reinilde Heyrman, Eugene Sullivan, Carlos Fernandez
  • 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS
    Publication number: 20190092746
    Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.
    Type: Application
    Filed: May 29, 2018
    Publication date: March 28, 2019
    Applicant: AstraZeneca AB
    Inventors: Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Vasantha Krishna KADAMBAR, Chandrashekar Reddy C MURUGAN, Andiappan MURUGAN
  • NOVEL COMPOUNDS
    Publication number: 20190084934
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Application
    Filed: June 4, 2018
    Publication date: March 21, 2019
    Applicant: AstraZeneca AB
    Inventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever